share_log
Reuters ·  17:21
U.S.-Listed Shares of Mesoblast Surge 49% Premarket After FDA Approves Cell Therapy for Graft-Versus-Host Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment